spacer
home > ict > spring 2021 > unlocking the potential of car t therapy
PUBLICATIONS
International Clinical Trials

Unlocking the Potential of CAR T Therapy



The treatment landscape for haematology is a constantly evolving one. Tremendous advances have been made in recent decades, which have provided us with innovative ways to tackle haematological malignancies. Though the progress we’ve seen has been inspiring, we are still coming up against limits. When current treatments are not, or are no longer, effective, or when patients are unable to tolerate them, alternative treatment approaches are needed (1-3).

Targeted, personalised medicines are a frontier in this endeavour, offering the potential to allow us to move away from the traditional ‘one-size-fits-all’ approach to cancer research and development, and instead focus on finding the right treatment for the right patient at the right time. Within this category, CAR T therapy is an area that offers real promise – but in order to fulfil its therapeutic potential, the pharmaceutical industry, and health systems more broadly, must overcome challenges in how this treatment is delivered to patients, and the infrastructure and logistics required for doing this effectively.

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
About the Author

Mircea Cubillos is the Regional Commercial Strategy Leader, Haematology EMEA for Janssen. Mircea has been with the wider Johnson & Johnson organisation since 2001, and possesses cross-sector business acumen, a strong customer focus, passion for talent development and diversity, equality, and inclusion, and resilience in managing challenging market conditions. During a career that has spanned countries including Brazil, Mexico, Venezuela, and the US, Mircea launched a new go-to-market strategy for Colombia, Puerto Rico, and Central America to better meet current and future customer needs, and he now drives the growth of Janssen's haematology work in the EMEA region.
Print this page
Send to a friend
Privacy statement
News and Press Releases

Avantor to Acquire Masterflex; Expands Proprietary Single-Use Offering for Bioproduction

RADNOR, Pa., Sept. 7, 2021 /PRNewswire/ – Avantor, Inc. (NYSE: AVTR), a leading global provider of mission-critical products and services to customers in the life sciences and advanced technologies & applied materials industries, today announced that it has entered into a definitive agreement to acquire the Masterflex bioprocessing business and related assets (collectively "Masterflex") of Antylia Scientific.
More info >>

White Papers

Planning the Execution of a Viral Clearance Study

Eurofins BioPharma Product Testing

Viral clearance studies are a necessary component of any regulatory submission for clinical trials or commercial product approval for all biopharmaceutical products. These studies are performed to evaluate the capability of the purification process to remove or inactivate viruses that could potentially contaminate the starting material. They are complex studies that require substantial financial and personnel resources, as well as specialized scientific expertise to perform. As such, viral clearance studies are often performed at a qualified contract testing laboratory rather than in-house. When multiple parties are involved in this process, clear communication and a comprehensive understanding of the approach and timeline is critical.
More info >>

 

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement